This Week in Ketamine: March 10, 2023 Edition | Latest Insights for Depression and Anxiety Treatment | ISHA Health

This week in ketamine, we have nine papers covering various topics, including clinical evidence of ketamine's potential for PTSD treatment, toxicity patterns associated with chronic ketamine exposure, real-world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder, cortical inhibition function associated with baseline suicidal symptoms, and post-ketamine suicidal symptom reduction, nano-hesperetin attenuating ketamine-induced schizophrenia-like symptoms in mice, different QT correction methods for nonclinical safety assessment in ketamine-anaesthetized Indian rhesus monkeys, the effect of S-ketamine on chronic post-surgical pain, treatment and outcome following substantial ketamine overdose in a dog, and a comparison of the patient state index and bispectral index in patients with complex regional pain syndrome undergoing ketamine infusion therapy.

Here is a summary of each paper:

1. The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence" by Ragnhildstveit et al. (2023): The authors reviewed clinical evidence on ketamine in PTSD, characterizing the prevalence of PTSD between ketamine and non-ketamine patients.

2. Toxicity patterns associated with chronic ketamine exposure" by Hottat and Hantson (2023): The authors reported the association between ketamine snorting and pneumomediastinum and showed that ketamine abuse caused various toxicities.

3. Real World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Depression with Comorbid Borderline Personality Disorder" by Danayan et al. (2023): The authors reported the real-world effectiveness of repeated ketamine infusions in people with BPD and TRD.

4. Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant" by Chen et al. (2023): The authors showed that cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression.

5. Nano-hesperetin attenuates ketamine-induced schizophrenia-like symptoms in mice: participation of antioxidant parameters" by Moghaddam et al. (2023): The authors reported that persistent ketamine treatment increases SCZ-like behaviors and oxidative stress and showed that Nano-hesperetin attenuated ketamine-induced schizophrenia-like symptoms in mice.

6. Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anaesthetized Indian rhesus monkeys (Macaca mulatta)" by Bhatt et al. (2023): The authors compared different QT correction methods for nonclinical safety assessment in ketamine-anaesthetized Indian rhesus monkeys.

7. A single preoperative dose of S-ketamine has no beneficial effect on chronic post-surgical pain in patients undergoing video-assisted thoracoscopic surgical lung" by Zhou et al. (2023): The authors investigated the efficacy of intravenous S-ketamine for chronic post-surgical pain in patients undergoing video-assisted thoracoscopic surgical lung.

8. Treatment and outcome following substantial ketamine overdose in a dog" by Parker et al. (2023): The authors reported an iatrogenic 338 times overdose of ketamine in a dog and the successful treatment.

9. Comparison of the patient state index and bispectral index in patients with complex regional pain syndrome undergoing ketamine infusion therapy: Case series" by Lee and Lee (2023): The authors compared the patient state index and bispectral index in patients with complex regional pain syndrome undergoing ketamine infusion therapy.

‍

Reference:

1. Ragnhildstveit, A., Roscoe, J., Bass, L. C., Averill, C. L., & Ross, S. (2023). The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence. Therapeutic Advances in Psychopharmacology, 13, 204512532310905.
2. Hottat, A., & Hantson, P. (2023). Toxicity patterns associated with chronic ketamine exposure. Toxicologie Analytique et Clinique, 35(1), 1-9.
3. Danayan, K., Chisamore, N., Rodrigues, N. B., Meehan, K., Mehra, S., & Fefferman, A. (2023). Real World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Depression with Comorbid Borderline Personality Disorder. Psychiatry Research, 308, 114227.
4. Chen, M. H., Su, T. P., Chen, L. F., Li, C. T., Wu, H. J., Lin, W. C., ... & Chen, Y. W. (2023). Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression. Journal of Psychiatric Research, 144, 65-72.
5. Moghaddam, A. H., Parhizgar, M., jelodar, S., Eslami, A., & Jahanihashemi, H. (2023). Nano-hesperetin attenuates ketamine-induced schizophrenia-like symptoms in mice: participation of antioxidant parameters. Psychopharmacology, 240(3), 703-711.
6. Bhatt, L. K., Shah, C. R., Patel, R. J., Patel, S. D., Patel, S. R., Patel, S. N., & Gohil, D. J. (2023). Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anaesthetized Indian rhesus monkeys (Macaca mulatta). Toxicology Mechanisms and Methods, 33(2), 129-139.
7. Zhou, R., Zhang, Y., Tang, S., Zhang, X., Wang, Y., Liu, Y., & Liu, C. (2023). A single preoperative dose of S-ketamine has no beneficial effect on chronic post-surgical pain in patients undergoing video-assisted thoracoscopic surgical lung resection. Journal of Cardiothoracic and Vascular Anesthesia, 37(1), 75-81.
8. Parker, L. A., Krebs, K., Pan, P. L., Varner, K. M., & Hoddinott, K. L. (2023). Treatment and outcome following substantial ketamine overdose in a dog. The Canadian Veterinary Journal, 64(1), 73-76.
9. Lee, K. H., & Lee, S. E. (2023). Comparison of the patient state index and bispectral index in patients with complex regional pain syndrome undergoing ketamine infusion therapy: Case series. Bali Journal of Anesthesiology, 7(1), 59-62.
10. Zanfaly, H. E. (2023). Ketamine as an Adjuvant To Bupivacaine In Caudal Block For Pediatric Patients Undergoing Lower Abdominal Surgeries. Zagazig University Medical Journal, 29(1), 59-67.

‍